BridgeBio Pharma, Inc. (NASDAQ: BBIO) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning BridgeBio announced seven collaborations with US and Canadian academic and research institutions to take its total up to 20. It caught my eye. . . . It’s especially timely, as one of things that is currently bubbling up in my conversations with folks is this topic of portfolio-based biotechs. We’re seeing more of this now more than ever. Obviously, there is BridgeBio. Centessa launched a month ago with a $250MM Series A. Marc Appel’s Orange Grove Bio continues to progress — still relatively largely in stealth mode, it’s maturing — keep an eye on it. Benjamine Liu’s TrialSpark, even earlier, positives going on there — keep this one on your radar as well. McKinsey wrote a piece on the biotech portfolio model as well recently; ICYMI, here’s the link.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About BridgeBio Pharma, Inc.
BridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company’s first approved therapy. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit www.bridgebio.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
